NewLimit
Backed by
Raised $130M Series B on May 6, 2025
NewLimit is a biotechnology company working to radically extend human healthspan. They are developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells.
Data Scientist, Computational Biology
South San Francisco, CA · Posted on Apr 24, 2025
Group Leader, Functional Genomics
South San Francisco · Posted on Apr 21, 2025
Group Leader, Immunology
South San Francisco, CA · Posted on Apr 21, 2025
Scientist/Senior Scientist, Functional Genomics
South San Francisco, CA · Posted on Apr 21, 2025
Scientist/Senior Scientist, Vascular
South San Francisco, CA · Posted on Apr 21, 2025
Senior/Research Associate, Immunology
South San Francisco, CA · Posted on Apr 21, 2025
